[go: up one dir, main page]

EA200601065A1 - Производные имидазола, способы их получения и применения - Google Patents

Производные имидазола, способы их получения и применения

Info

Publication number
EA200601065A1
EA200601065A1 EA200601065A EA200601065A EA200601065A1 EA 200601065 A1 EA200601065 A1 EA 200601065A1 EA 200601065 A EA200601065 A EA 200601065A EA 200601065 A EA200601065 A EA 200601065A EA 200601065 A1 EA200601065 A1 EA 200601065A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
imidazol
production
methods
application
Prior art date
Application number
EA200601065A
Other languages
English (en)
Other versions
EA010031B1 (ru
Inventor
Бенуа Кенда
Филипп Мишель
Янник Кесне
Original Assignee
Юсб, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб, С.А. filed Critical Юсб, С.А.
Publication of EA200601065A1 publication Critical patent/EA200601065A1/ru
Publication of EA010031B1 publication Critical patent/EA010031B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

В заявке описаны производные имидазола формулы (I), способы их получения, содержащие их фармацевтические композиции и их применение в качестве лекарственных препаратов.
EA200601065A 2003-12-02 2004-11-29 Производные имидазола, способы их получения и применения EA010031B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03027614 2003-12-02
PCT/EP2004/013516 WO2005054188A1 (en) 2003-12-02 2004-11-29 Imidazole derivatives, processes for preparing them and their uses

Publications (2)

Publication Number Publication Date
EA200601065A1 true EA200601065A1 (ru) 2006-12-29
EA010031B1 EA010031B1 (ru) 2008-06-30

Family

ID=34639269

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601065A EA010031B1 (ru) 2003-12-02 2004-11-29 Производные имидазола, способы их получения и применения

Country Status (16)

Country Link
US (2) US7244747B2 (ru)
EP (2) EP2050736A1 (ru)
JP (1) JP2007513105A (ru)
KR (1) KR20060110349A (ru)
CN (1) CN1906160A (ru)
AT (1) ATE424384T1 (ru)
AU (1) AU2004295083B2 (ru)
BR (1) BRPI0417157A (ru)
CA (1) CA2546970C (ru)
DE (1) DE602004019814D1 (ru)
EA (1) EA010031B1 (ru)
ES (1) ES2323313T3 (ru)
MX (1) MXPA06006026A (ru)
NO (1) NO20063062L (ru)
WO (1) WO2005054188A1 (ru)
ZA (1) ZA200604410B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4970057B2 (ja) * 2004-02-24 2012-07-04 アラーガン、インコーポレイテッド ボツリヌス毒素スクリーニングアッセイ
ES2441178T3 (es) 2005-06-01 2014-02-03 Ucb Pharma, S.A. Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central
EP1926710B1 (en) * 2005-09-15 2014-11-12 UCB Pharma S.A. 4-Substituted pyrrolidin-2-ones and their use
TWI386405B (zh) 2006-09-05 2013-02-21 咪唑衍生物
EP2152262A2 (en) * 2007-04-27 2010-02-17 UCB Pharma, S.A. New heterocyclic derivatives useful for the treatment of cns disorders
EP2017273A1 (en) 2007-07-18 2009-01-21 Laboratorios del Dr. Esteve S.A. Process for the enantioselective preparation of pregabalin
US7883745B2 (en) * 2007-07-30 2011-02-08 Micron Technology, Inc. Chemical vaporizer for material deposition systems and associated methods
JP2011518841A (ja) * 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド Ｉｄｏ阻害剤
CN107243007A (zh) * 2008-10-16 2017-10-13 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
US20120171125A1 (en) * 2009-08-07 2012-07-05 Ucb Pharma, S.A. Methods for Enhancing the Cognitive Function
HRP20160263T1 (hr) 2009-10-23 2016-04-08 Ucb Biopharma Sprl Derivati 2-okso-1-pirolidinil imidazotiadiazola
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
CA2831830C (en) 2011-04-18 2017-12-12 Ucb Pharma, S.A. 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
WO2014012563A1 (en) * 2012-07-20 2014-01-23 Ucb Pharma, S.A. Compounds for enhancing the cognitive function
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
CN105142623A (zh) 2013-03-15 2015-12-09 艾吉因生物股份有限公司 用于改善认知功能的方法和组合物
AU2015208233B2 (en) 2014-01-21 2019-08-29 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
RU2654065C1 (ru) * 2017-03-16 2018-05-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Уфимский государственный нефтяной технический университет" Способ получения N-оксиметиламинов
CN106866494A (zh) * 2017-03-20 2017-06-20 安徽金鼎医药股份有限公司 一种格列齐特中间体八氢环戊烷并[c]吡咯的制备方法
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903110A (en) 1972-04-27 1975-09-02 Gaf Corp N-(2-pyrrolidinonyl) methyl carbamate derivatives
AT352119B (de) * 1975-07-29 1979-09-10 Celamerck Gmbh & Co Kg Verfahren zur herstellung neuer imidazol-bzw. triazolderivate
GB1582351A (en) * 1977-02-10 1981-01-07 Ucb Sa Disubstituted ureas and thioureas
US4178167A (en) * 1977-06-16 1979-12-11 Gaf Corporation Herbicidal N-(haloacetyl)-N-(N'-methylenepyrrolidonyl)-2-alkoxyanilines useful as herbicides
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
AU2869092A (en) * 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
JPH06220044A (ja) * 1991-12-25 1994-08-09 Mitsubishi Kasei Corp ベンズアミド誘導体
WO1997037655A1 (en) * 1996-04-10 1997-10-16 Merck & Co., Inc. αvβ3 ANTAGONISTS
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Also Published As

Publication number Publication date
BRPI0417157A (pt) 2007-03-06
MXPA06006026A (es) 2006-08-23
NO20063062L (no) 2006-08-30
US20050137241A1 (en) 2005-06-23
JP2007513105A (ja) 2007-05-24
DE602004019814D1 (de) 2009-04-16
ZA200604410B (en) 2008-09-25
ATE424384T1 (de) 2009-03-15
EP1706376A1 (en) 2006-10-04
CN1906160A (zh) 2007-01-31
AU2004295083B2 (en) 2010-08-19
ES2323313T3 (es) 2009-07-13
KR20060110349A (ko) 2006-10-24
US20080081832A1 (en) 2008-04-03
EP2050736A1 (en) 2009-04-22
AU2004295083A1 (en) 2005-06-16
WO2005054188A1 (en) 2005-06-16
EA010031B1 (ru) 2008-06-30
CA2546970C (en) 2011-04-26
EP1706376B1 (en) 2009-03-04
US7244747B2 (en) 2007-07-17
US7763644B2 (en) 2010-07-27
CA2546970A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
EA200601065A1 (ru) Производные имидазола, способы их получения и применения
ATE433447T1 (de) Pyrimiidinverbindungen
SE0302232D0 (sv) Novel Compounds
ATE384061T1 (de) Imidazo- und thiazolopyridine als jak3-kinase- inhibitoren
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
EA200700168A1 (ru) Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
HRP20070076A2 (en) Pyrimidine derivatives
CY1109568T1 (el) Ενωσεις βενζο(d)ισοξαζολ-3-υλαμινης και η χρησιμοποιηση τους σαν προσδεματα υποδοχεα βανιλλοειδων
MXPA04003007A (es) Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades.
TW200732323A (en) Organic compounds
SE0200920D0 (sv) Novel compounds
SE0401762D0 (sv) Novel compounds
ES2335410T8 (es) Derivados de aminopropanol.
TNSN04250A1 (en) Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof.
EA200801608A1 (ru) Производные бензимидазолонкарбоновой кислоты
EA200600605A1 (ru) Перегруппированные пентанолы, способ их получения и их применение в качестве противовоспалительных средств
JO2734B1 (en) Organic compounds
EA200702375A1 (ru) Производные мочевины, способы их получения и применения
BR0318521A (pt) arilindenopiridinas e arilindenopirimidinas e métodos terapêuticos e profiláticos relacionados
DK1745010T3 (da) Substituerede cyklohexyl-1,4-diaminderivater
NO20061045L (no) Imidazolderivater
DK1373218T3 (da) Imidazolylderivater til anvendelse som histamin H3-receptorligander
ATE317380T1 (de) Bernsteinsäurederivate
ATE374751T1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
DK1598366T3 (da) Somatostatinanaloger

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU